EMA sets forward proposals to revise guidance on first-in-human clinical trials

The European Medicines Agency (EMA), in cooperation with the European Commission and the Member States of the European Union (EU), has proposed changes to the current guidance on first-in-human clinical trials. These changes are designed to hopefully further improve strategies which help to identify and mitigate risks to trial participants.

To read more about this, please click here.

Tagged with

Published on 25. July 2016 in News EU